Production (Stage)
Anika Therapeutics, Inc.
ANIK
$11.24
-$0.53-4.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -14.49% | -21.03% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -14.49% | -21.03% | |||
| Cost of Revenue | -10.75% | -65.51% | |||
| Gross Profit | -17.20% | 1,131.32% | |||
| SG&A Expenses | 13.97% | -40.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.81% | -51.78% | |||
| Operating Income | -4,184.00% | 99.60% | |||
| Income Before Tax | -10,281.58% | 100.14% | |||
| Income Tax Expenses | -96.47% | 9.41% | |||
| Earnings from Continuing Operations | -59.21% | 91.69% | |||
| Earnings from Discontinued Operations | 95.28% | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 77.71% | 26.92% | |||
| EBIT | -4,184.00% | 99.60% | |||
| EBITDA | -228.93% | 109.19% | |||
| EPS Basic | 77.28% | 25.96% | |||
| Normalized Basic EPS | -712.68% | 102.66% | |||
| EPS Diluted | 77.07% | 26.11% | |||
| Normalized Diluted EPS | -714.91% | 102.65% | |||
| Average Basic Shares Outstanding | -1.92% | -1.30% | |||
| Average Diluted Shares Outstanding | -2.23% | -0.98% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||